Advisory OTCs? GSK Weighs Third Class Paradigm With Xenical In Mind
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline Consumer Healthcare is internally discussing the impact a third class of pharmacy-only drugs could have on the self-care market